Pdt Partners, LLC Arbutus Biopharma Corp Transaction History

Pdt Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $181,250 - $254,474	-72,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $227,650 - $350,900	72,500 New	72,500 $241,000
Q2 2019 Aug 14, 2019	SELL	$1.46 - $4.44 $44,092 - $134,088	-30,200 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.5 - $9.66 $21,525 - $59,409	6,150 Added 25.57%	30,200 $116,000
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $336,882 - $530,000	-42,915 Reduced 64.09%	24,050 $227,000

Q2 2018 Aug 14, 2018	SELL	$5.0 - $7.35 $27,675 - $40,682	-5,535 Reduced 7.63%	66,965 $489,000
Q1 2018 May 15, 2018	SELL	$4.4 - $6.05 $46,200 - $63,525	-10,500 Reduced 12.65%	72,500 $363,000
Q4 2017 Feb 14, 2018	BUY	$4.45 - $7.7 $369,350 - $639,100	83,000	83,000 $419,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $469M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.